202 related articles for article (PubMed ID: 34778768)
1. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.
Wu C; Cao X; Zhang X
RSC Med Chem; 2021 Oct; 12(10):1672-1679. PubMed ID: 34778768
[TBL] [Abstract][Full Text] [Related]
2. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
3. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
[TBL] [Abstract][Full Text] [Related]
4. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
[TBL] [Abstract][Full Text] [Related]
5. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
6. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
7. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
[TBL] [Abstract][Full Text] [Related]
8. VISTA: A Promising Target for Cancer Immunotherapy?
Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
[TBL] [Abstract][Full Text] [Related]
9. Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.
Jung M; Bonavida B
Crit Rev Immunol; 2022; 42(4):37-49. PubMed ID: 37022358
[TBL] [Abstract][Full Text] [Related]
10. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
[TBL] [Abstract][Full Text] [Related]
11. Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).
Wang T; Wang K; Zhang Y; Zhang K; Cai S; Jiang S; Xiao Y; Zhang X
J Med Chem; 2023 Sep; 66(17):11881-11892. PubMed ID: 37594853
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA).
Gabr MT; Gambhir SS
J Am Chem Soc; 2020 Sep; 142(38):16194-16198. PubMed ID: 32894020
[TBL] [Abstract][Full Text] [Related]
13. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
14. VISTA: A Novel Checkpoint for Cancer Immunotherapy.
Gao Y; He Y; Tang Y; Chen ZS; Qu M
Drug Discov Today; 2024 May; 29(7):104045. PubMed ID: 38797321
[TBL] [Abstract][Full Text] [Related]
15. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
16. VSIG-3 as a ligand of VISTA inhibits human T-cell function.
Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V
Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083
[TBL] [Abstract][Full Text] [Related]
17. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
18. Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection.
Zheng M; Zhang Z; Yu L; Wang Z; Dong Y; Tong A; Yang H
Front Immunol; 2023; 14():1194421. PubMed ID: 37435070
[TBL] [Abstract][Full Text] [Related]
19. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
[TBL] [Abstract][Full Text] [Related]
20. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
Noelle RJ; Lines JL; Lewis LD; Martell RE; Guillaudeux T; Lee SW; Mahoney KM; Vesely MD; Boyd-Kirkup J; Nambiar DK; Scott AM
Front Oncol; 2023; 13():1225081. PubMed ID: 37795437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
